Plasmapheresis for people with ALS who have anti-NRIP autoantibodies
Tests plasmapheresis in people with ALS who have anti-NRIP autoantibodies in their blood.
Plain-language title generated from the registry record
Registry title: Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP 2 (PALADIN2)
Key facts
- Where
- Taipei City, TaiwanSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with ALS who have anti-NRIP autoantibody in their blood plasma. Everyone receives plasmapheresis.
- Age
- Above 20 years old (minimum age 20 years)
- Sex
- All sexes can join.
- Disease stage
- ALS. Special subtypes such as primary lateral sclerosis, progressive muscular atrophy, flail arm syndrome and flail leg syndrome cannot join.
- Biomarker or test result
- Anti-NRIP autoantibody must be present in the plasma.
Main reasons for not taking part
- Under permanent ventilator support
- Cannot receive plasmapheresis or the serial examinations
- Pregnancy
- Blood fibrinogen level below 50 mg/dl
- Special ALS subtypes (primary lateral sclerosis, progressive muscular atrophy, flail arm or flail leg syndrome)
Read by machine on 9 November 2026.
Where in Taiwan
- National Taiwan University HospitalTaipei City, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Taiwan University Hospital
- Trial code
- NCT07726563
- Record updated
- 24 July 2026
- Original description
10-20% of patients with ALS have anti-NRIP autoantibody and the titer of anti-NRIP autoantibody is correlated with motor functional decline and mortality in ALS. The PALADIN2 clinical trial is a single arm study, which intends to enroll 20 ALS patients having anti-NRIP autoantibody in plasma. Patients will receive 3 courses of plasmapheresis per 3 months in order to maintain low concentration of anti-NRIP autoantibody in plasma. The study will follow up these patients for another 6 months after plasmapheresis. This project will potentially confirm the efficacy and safety of plasmapheresis for ALS patients having anti-NRIP autoantibody.Read full original descriptionShow less
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP 2 (PALADIN2)
10-20% of patients with ALS have anti-NRIP autoantibody and the titer of anti-NRIP autoantibody is correlated with motor functional decline and mortality in ALS. The PALADIN2 clinical trial is a single arm study, which intends to enroll 20 ALS patients having anti-NRIP autoantibody in plasma. Patients will receive 3 courses of plasmapheresis per 3 months in order to maintain low concentration of anti-NRIP autoantibody in plasma. The study will follow up these patients for another 6 months after plasmapheresis. This project will potentially confirm the efficacy and safety of plasmapheresis for ALS patients having anti-NRIP autoantibody.
Inclusion: ALS patients above 20-year-old who have anti-NRIP autoantibody in plasma; Agree to receive plasmapheresis treatment; Agree to participate in the study and receive serial examinations.
Exclusion: Belong to special subtype of ALS, such as primary lateral sclerosis, progressive muscular atrophy, flail arm syndrome, flail leg syndrome; Blood fibrinogen level below 50 mg/dl; Under permanent ventilator support; Cannot receive plasmapheresis treatment or serial examinations; Under pregnancy.